MediciNova, Inc. is a publicly-traded biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Through strategic alliances primarily with Japanese pharmaceutical companies, MediciNova holds rights to a diversified portfolio of clinical and preclinical product candidates, each of which MediciNova believes has a well-characterized and differentiated therapeutic profile, attractive commercial potential and patent assets having claims of commercially adequate scope. MediciNova’s pipeline includes clinical-stage compounds for the treatment of acute exacerbations of asthma and COPD, progressive multiple sclerosis, methamphetamine addiction, neuropathic pain, asthma, interstitial cystitis, and solid tumor cancers. MediciNova’s current strategy is to focus on MN-166 (ibudilast) for neurological disorders, MN-221 for the treatment of acute exacerbations of asthma, and MN-001 for NASH. MediciNova may pursue development independently or establish a strategic collaboration to support further development of its programs. MediciNova will seek to monetize its other product candidates at key value inflection points. MediciNova’s executive management team has extensive global development, regulatory, commercial and financial experience, and manages its international clinical and manufacturing operations through efficient and cost-effective utilization of contract research organizations. Headquartered in La Jolla, California, MediciNova has approximately 15 employees.